Is second-line anti-tuberculosis drug susceptibility testing reliable?

被引：1

作者：

Kim, SJ ^{[1
]}

Espinal, MA

Abe, C

Bai, GH

Boulahbals, F

Fattorinit, L

Gilpin, C

Hoffner, S

Kam, KM

Martin-Casabona, N

Rigouts, L

Vincent, V

机构：

[1] WHO, Stop TB Dept, CH-1211 Geneva, Switzerland

[2] Japan Anti TB Assoc, Res Inst TB, Tokyo, Japan

[3] Korea Natl TB Assoc, Korean Inst TB, Seoul, South Korea

[4] Inst Pasteur Algerie Alger, Lab TB, Algiers, Algeria

[5] Inst Super San Lab Bacteriol & Med Mycol, Rome, Italy

[6] Prince Charles Hosp, Queensland Mycobacterium Reference Lab, Brisbane, Qld 4032, Australia

[7] Swedish Inst Infect Dis Control, Solna, Sweden

[8] Dept Hlth, TB Reference Lab, Hong Kong, Hong Kong, Peoples R China

[9] Ciudad Sanitaria & Univ Vall Hebron, Serv Microbiol Hosp, E-08035 Barcelona, Spain

[10] Inst Trop Med, Mycobacteriol Unit, Dept Microbiol, B-2000 Antwerp, Belgium

[11] Inst Pasteur, Ctr Natl Reference Mycobacteries, Paris, France

来源：

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE | 2004年 / 8卷 / 09期

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

引用

页码：1157 / 1158

页数：2

共 50 条

[1] Second-line anti-tuberculosis drug concentrations for susceptibility testing in the MODS assay
Patrick Fitzwater, Sean
Andrew Sechler, G.
Jave, Oswaldo
Coronel, Jorge
Mendoza, Alberto
Gilman, Robert H.
Friedland, Jon S.
Moore, David A. J.
EUROPEAN RESPIRATORY JOURNAL, 2013, 41 (05) : 1163 - 1171
[2] Global availability of susceptibility testing for second-line anti-tuberculosis agents
Lazarchik, A.
Nyaruhirira, A. U.
Chiang, C-Y
Wares, F.
Horsburgh, C. R., Jr.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2022, 26 (06) : 524 - +
[3] First proficiency testing of second-line anti-tuberculosis drug susceptibility testing in 12 provinces of China
Jiang, G-L
Chen, X.
Song, Y.
Zhao, Y.
Huang, H.
Kam, K. M.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2013, 17 (11) : 1491 - 1494
[4] Availability of second-line drugs and anti-tuberculosis drug susceptibility testing in China: a situational analysis
He, G. X.
van den Hof, S.
Borgdorff, M. W.
van der Werf, M. J.
Cheng, S. M.
Hu, Y. L.
Zhang, L. X.
Wang, L. X.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2010, 14 (07) : 884 - 889
[5] Evaluation of the GenoType® MTBDRsl assay for susceptibility testing of second-line anti-tuberculosis drugs
Said, H. M.
Kock, M. M.
Ismail, N. A.
Baba, K.
Omar, S. V.
Osman, A. G.
Hoosen, A. A.
Ehlers, M. M.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2012, 16 (01) : 104 - 109
[6] Second-line anti-tuberculosis drug resistance testing in Ghana identifies the first extensively drug-resistant tuberculosis case
Osei-Wusu, Stephen
Omari, Michael Amo
Asante-Poku, Adwoa
Otchere, Isaac Darko
Asare, Prince
Forson, Audrey
Otu, Jacob
Antonio, Martin
Yeboah-Manu, Dorothy
INFECTION AND DRUG RESISTANCE, 2018, 11 : 239 - 246
[7] Proficiency testing of first- and second-line anti-tuberculosis drugs in Italy
Fattorini, Lanfranco
Migliori, Giovanni Battista
Cassone, Antonio
Mustazzolu, Alessandro
Piccaro, Giovanni
Filippini, Perla
Cirillo, Daniela Maria
Borroni, Emanuele
EUROPEAN RESPIRATORY JOURNAL, 2012, 39 (05) : 1263 - 1266
[8] First- and second-line anti-tuberculosis drug resistance in Northwest Ethiopia
Tessema, B.
Beer, J.
Emmrich, F.
Sack, U.
Rodloff, A. C.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2012, 16 (06) : 805 - 811
[9] Performance of the GenoType MTBDRsl assay for the detection second-line anti-tuberculosis drug resistance
Lee, Young Seok
Lee, Bo Young
Jo, Kyung-Wook
Shim, Tae Sun
JOURNAL OF INFECTION AND CHEMOTHERAPY, 2017, 23 (12) : 820 - 825
[10] Safety and Tolerability Profile of Second-Line Anti-Tuberculosis Medications
Ramachandran, Geetha
Swaminathan, Soumya
DRUG SAFETY, 2015, 38 (03) : 253 - 269

← 1 2 3 4 5 →